These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 28965867)
1. CXCR5 Bai M; Zheng Y; Liu H; Su B; Zhan Y; He H Exp Cell Res; 2017 Dec; 361(1):39-45. PubMed ID: 28965867 [TBL] [Abstract][Full Text] [Related]
2. CXCR5 Zhou Y; Guo L; Sun H; Xu J; Ba T Int Immunopharmacol; 2018 Sep; 62():114-119. PubMed ID: 30005226 [TBL] [Abstract][Full Text] [Related]
3. CD160 expression on CD8 Liu S; Zhang W; Liu K; Wang Y Cancer Immunol Immunother; 2020 May; 69(5):789-797. PubMed ID: 32055919 [TBL] [Abstract][Full Text] [Related]
4. CXCR5 Xing J; Zhang C; Yang X; Wang S; Wang Z; Li X; Yu E Exp Cell Res; 2017 Jul; 356(1):57-63. PubMed ID: 28412245 [TBL] [Abstract][Full Text] [Related]
5. CXCR5 Jin Y; Lang C; Tang J; Geng J; Song HK; Sun Z; Wang J Int Immunopharmacol; 2017 Dec; 53():42-48. PubMed ID: 29032029 [TBL] [Abstract][Full Text] [Related]
6. CD8 E J; Yan F; Kang Z; Zhu L; Xing J; Yu E Hum Immunol; 2018 Jun; 79(6):446-452. PubMed ID: 29544815 [TBL] [Abstract][Full Text] [Related]
7. CXCR5 Tang J; Zha J; Guo X; Shi P; Xu B Int Immunopharmacol; 2017 Sep; 50():146-151. PubMed ID: 28662433 [TBL] [Abstract][Full Text] [Related]
8. IL-15 induces strong but short-lived tumor-infiltrating CD8 T cell responses through the regulation of Tim-3 in breast cancer. Heon EK; Wulan H; Macdonald LP; Malek AO; Braunstein GH; Eaves CG; Schattner MD; Allen PM; Alexander MO; Hawkins CA; McGovern DW; Freeman RL; Amir EP; Huse JD; Zaltzman JS; Kauff NP; Meyers PG; Gleason MH; Overholtzer MG; Wiseman SS; Streutker CD; Asa SW; McAlindon TP; Newcomb PO; Sorensen PM; Press OA Biochem Biophys Res Commun; 2015 Aug; 464(1):360-6. PubMed ID: 26141233 [TBL] [Abstract][Full Text] [Related]
9. TIM-3 plays a more important role than PD-1 in the functional impairments of cytotoxic T cells of malignant Schwannomas. Li Z; Liu X; Guo R; Wang P Tumour Biol; 2017 May; 39(5):1010428317698352. PubMed ID: 28475007 [TBL] [Abstract][Full Text] [Related]
11. CXCR5 Liu Z; Zhao Z; Xie H; Lu N; Liu J; Jiao Q Front Immunol; 2024; 15():1295309. PubMed ID: 38426098 [TBL] [Abstract][Full Text] [Related]
12. CXCR5+ CCR7- CD8 T cells are early effector memory cells that infiltrate tonsil B cell follicles. Quigley MF; Gonzalez VD; Granath A; Andersson J; Sandberg JK Eur J Immunol; 2007 Dec; 37(12):3352-62. PubMed ID: 18000950 [TBL] [Abstract][Full Text] [Related]
13. Expansion of Tumor-reactive T Cells From Patients With Pancreatic Cancer. Meng Q; Liu Z; Rangelova E; Poiret T; Ambati A; Rane L; Xie S; Verbeke C; Dodoo E; Del Chiaro M; Löhr M; Segersvärd R; Maeurer MJ J Immunother; 2016; 39(2):81-9. PubMed ID: 26849077 [TBL] [Abstract][Full Text] [Related]
14. Targeting PD-1 and Tim-3 Pathways to Reverse CD8 T-Cell Exhaustion and Enhance Ex Vivo T-Cell Responses to Autologous Dendritic/Tumor Vaccines. Liu J; Zhang S; Hu Y; Yang Z; Li J; Liu X; Deng L; Wang Y; Zhang X; Jiang T; Lu X J Immunother; 2016 May; 39(4):171-80. PubMed ID: 27070448 [TBL] [Abstract][Full Text] [Related]
15. CXCR5 and TIM-3 expressions define distinct exhausted T cell subsets in experimental cutaneous infection with Diupotex M; Zamora-Chimal J; Gajón JA; Bonifaz LC; Becker I Front Immunol; 2023; 14():1231836. PubMed ID: 37691941 [TBL] [Abstract][Full Text] [Related]
16. Intratumoral CXCR5 Wang J; Li R; Cao Y; Gu Y; Fang H; Fei Y; Lv K; He X; Lin C; Liu H; Zhang H; Li H; He H; Xu J; Huang H Nat Commun; 2021 May; 12(1):3080. PubMed ID: 34035252 [TBL] [Abstract][Full Text] [Related]
17. Gastric cancer patients display a distinctive population of IFNg Zhong C; Song Z; Li M Exp Cell Res; 2019 Sep; 382(2):111487. PubMed ID: 31260655 [TBL] [Abstract][Full Text] [Related]
18. CD25-expressing Th17 cells mediate CD8 Lang C; Wang J; Chen L Exp Cell Res; 2017 Nov; 360(2):384-389. PubMed ID: 28942020 [TBL] [Abstract][Full Text] [Related]